Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. EST on Thursday, February 27.
Conference Call and Webcast Details
To listen to the conference call, dial in approximately ten minutes before the scheduled 4:30 P.M. time to (253) 237-1170 or toll free at (877) 372-0867. Please reference conference ID 43774065 or the Opexa Therapeutics Earnings Call.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts